MedTrace Logo

A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)

NCT01462292 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2017-10-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if GSK2402968 is effective in the treatment of ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping. Two doses of GSK2402968 and placebo will be used in this study.

Conditions

  • Muscular Dystrophies

Interventions

DRUG

GSK2402968 3mg/kg/week

Comparison of 2 doses of GSK2402968

DRUG

GSK2402968 6 mg/kg/week

Comparison of 2 doses of GSK2402968

DRUG

Placebo to match GSK2402968 3 mg/kg/week

Matched placebo

DRUG

Placebo to match GSK2402968 6 mg/kg/week

Matched Placebo

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-26
Primary Completion
2013-05-21
Completion
2013-11-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01462292 on ClinicalTrials.gov